The European medicines regulator has OK’d a label update for AstraZeneca’s (LSE: AZN) Lokelma (sodium zirconium cyclosilicate), to include people with hyperkalemia on stable hemodialysis.
Lokelma is an innovative non-resin-based potassium binder, which offers improved tolerability over traditional resin-based products used in this treatment setting.
AstraZeneca acquired the novel therapy through its $2.7 billion buyout of California’s ZS Pharma, in 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze